Tezacaftor

A medication used in the treatment of cystic fibrosis

Tezacaftor
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Tezacaftor is a medication used in the management of cystic fibrosis, a genetic disorder that affects the lungs and other organs. It is often used in combination with other drugs to improve the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is defective in individuals with cystic fibrosis.

Mechanism of Action

Tezacaftor works by correcting the folding of the CFTR protein, allowing it to reach the cell surface where it can function properly. This action helps to improve the movement of chloride ions across cell membranes, which is impaired in cystic fibrosis patients. By enhancing CFTR function, tezacaftor helps to reduce the symptoms and complications associated with the disease.

Clinical Use

Tezacaftor is typically used in combination with other CFTR modulators, such as ivacaftor, to enhance its therapeutic effects. The combination therapy is indicated for patients with specific mutations in the CFTR gene that are responsive to this treatment approach. The use of tezacaftor in combination with ivacaftor has been shown to improve lung function and reduce pulmonary exacerbations in patients with cystic fibrosis.

Side Effects

Common side effects of tezacaftor include headache, nausea, and dizziness. Some patients may also experience respiratory symptoms such as cough or nasal congestion. It is important for patients to be monitored for any adverse reactions during treatment.

Administration

Tezacaftor is administered orally, usually in the form of a tablet. The dosage and frequency of administration depend on the specific combination therapy and the patient's individual response to treatment.

Related pages

• Cystic fibrosis
• Ivacaftor
• CFTR modulator

• 

  Tezacaftor